Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to MarketBeat Daily Ratings so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:BIOT

Biotech Acquisition (BIOT) Stock Price, News & Analysis

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)
Free BIOT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$10.14
▼
$10.19
50-Day Range
$10.08
▼
$10.32
52-Week Range
$8.30
▼
$10.41
Volume
44,400 shs
Average Volume
244,605 shs
Market Capitalization
$291.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BIOT stock logo

About Biotech Acquisition Stock (NASDAQ:BIOT)

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

BIOT Stock News Headlines

May 17 at 12:04 AM | markets.businessinsider.com
Buy Rating Affirmed for Ultragenyx Pharmaceutical Based on Clinical Updates and Market Valuation Disconnect
May 16, 2024 | msn.com
Johnson & Johnson to buy dermatology-focused biotech Proteologix
May 16, 2024 | msn.com
Mankind Pharma: Strong Q4, Acquisition Reports Not Enough To Power Stock
May 15, 2024 | bizjournals.com
Raleigh clinical research firm expands in four states with acquisition
May 15, 2024 | msn.com
Pharmaceutical giant Bayer AG trims workforce by 1500 amid slight sales decline
May 15, 2024 | msn.com
Biopharmaceutical mergers and acquisitions surge to new highs
May 10, 2024 | bizjournals.com
A second co-founder has left Forge Biologics following its more than $600M acquisition
May 8, 2024 | bizjournals.com
D.C. biotech mulling sweetened acquisition offer
May 8, 2024 | msn.com
Myonex Expands Pharmaceutical Services with Acquisition of Creapharm
May 8, 2024 | finance.yahoo.com
Arbor Biotechnologies Announces Acquisition of Serendipity
May 3, 2024 | finance.yahoo.com
Ephicacy Consulting Group Completes Acquisition of Advance Research Associates
May 2, 2024 | bizjournals.com
How Moderna's cost-cutting moves hit a Bay Area biotech
May 1, 2024 | bizjournals.com
Accounting giant wants to grow Albany footprint after Nuvalence acquisition
April 29, 2024 | msn.com
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical
April 29, 2024 | markets.businessinsider.com
Deciphera Up In Pre-market On News Of Acquisition By ONO Pharmaceutical For About $2.4 Bln
April 26, 2024 | msn.com
Eli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscape
April 26, 2024 | finanznachrichten.de
Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.
April 26, 2024 | markets.businessinsider.com
Buy Rating on Danaher: Strong Biotech Performance and Growth Potential Despite Market Challenges
April 26, 2024 | msn.com
Philadelphia-based Century Therapeutics Acquires Boston Biotechnology Firm Clade Therapeutics
April 25, 2024 | msn.com
Improved US biotech funding to aid FY25 growth, expects Jonathan Hunt, MD & CEO, Syngene International
April 24, 2024 | msn.com
Pharmaceutical giant Bayer’s manager cull will likely affect thousands of bosses—and the aspirin inventor thinks it will help its ‘brilliant’ Gen Z grads to thrive
April 24, 2024 | finance.yahoo.com
IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
April 22, 2024 | msn.com
MBK Partners acquires pharmaceutical wholesaler Geo-Young from Blackstone
April 19, 2024 | bizjournals.com
Spark co-founder, Harvard professor launch Watertown biotech with $54M
April 19, 2024 | seekingalpha.com
XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever
See More Headlines

Company Calendar

Today
5/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BIOT
CUSIP
N/A
CIK
1825413
Web
bioacq.com
Phone
212-227-1905
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,860,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-42.22%
Return on Assets
3.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.03
Quick Ratio
0.03

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.95) per share
Price / Book
-10.68

Miscellaneous

Outstanding Shares
28,750,000
Free Float
23,288,000
Market Cap
$291.81 million
Optionable
Not Optionable
Beta
-0.12

Key Executives

  • Dr. Michael Shleifer Ph.D. (Age 48)
    Chairman & CEO
  • Mr. Thomas Fratacci (Age 44)
    CFO & Treasurer
  • Mr. Ivan Jarry (Age 44)
    Chief Operating Officer
  • Mr. Albert F. Hummel M.B.A. (Age 76)
    Chief Investment Officer & Director

Key Competitors

View All Competitors

This page (NASDAQ:BIOT) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
Urgent Nvidia Warning
Altimetry
The Overlooked Retirement Asset You Probably Don’t Own
Crypto 101 Media
Shocking: One AI startup's revenue could surge 4,735%
Manward Press
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
CEO of Biggest AI Chipmaker Just Dropped a Bombshell…
Banyan Hill Publishing
Elon’s New Device is About to Shock the World
InvestorPlace
Most important medical advance in 100 years
The Oxford Club